Extensive prospective data similarly confirm that MLH1/MSH2 mutations confer a high risk of CRC, while MSH6 mutations only slightly increase the risk, and PMS2 shows no clear CRC penetrance [74]. Here, MSH2 is linked to colorectal carcinoma.